Clinical Trial Update: CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating CM082 in combination with everolimus in Chinese patients with metastatic renal cell carcinoma is currently status UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CM082
• Everolimus (everolimus)

Snippet

Sponsor: AnewPharma | Conditions: Renal Cell Cancer Metastatic | Phase 3 | Status: UNKNOWN